Kanaph focuses on the research and development of innovative therapeutic molecules to provide solutions for unmet medical needs in cancer and devastating diseases. We are developing a novel immunocytokine platform, TMEkine™, to activate and direct cytotoxic T-cells to tumor sites for efficient tumor eradication.
We are also taking novel therapeutic approaches with small molecules and biologics to remove immuno-suppresive environment in tumors for the enhancement of cancer-immunity cycle and immune stimulation. We aim to build next generation immuno-oncology pipelines, which will be further synergized by use with current successful checkpoint inhibitors. Our therapeutic approach also includes the development of small molecule pharmaceuticals to treat hard-to-cure cancers by targeting abnormal signaling pathways of specific cancers. Since Kanaph's technologies are platform-based, we expect our molecules to cover a variety of different cancers and diseases. We continue to identifiy best therapeutic approaches and develop first-in-class and best-in-class molecules.
TMEkine™ is a tumor microenvironment (TME)-targeting immunocytokine, one of Kanaph's immuno-oncology therapeutic platforms for the treatment and cure of devastating cancers. TME is an invasive area of tumor growth and metastasis where cancer cells communicate with nearby normal cells and tissues, and suppress the immune system for their survival. TMEkine™ is designed to target TME and restore the immune system at the tumor site.
The activated immune system will eradicate malignant cancer cells. Kanaph's TMEkine™ will be the next generation immuno-oncology therapeutic platform.
Immune/Immuno-oncology Fc Fusions
Kanaph's Fc-fusion proteins are designed to modulate our body's immune system at disease states. We utilize the benefit of Fc-fusion modalities to increase biophysical stability and serum half-life and extend therapeutic activity. Leveraging the advantages of Fc-fusions, Kanaph develops innovative Fc-fusion proteins for cancer and immune disorders. For immuno-oncology therapeutics, we expect our molecules will enhance anti-cancer effects by activating immune cells at TME. We add tumor-targeting moieties to the Fc-fusions to maximize efficacy and the therapeutic window. For immune diseases associated with hyperactive immune systems, our molecules will normalize the immune system.
Cancer-targeting Small Molecules
Kanaph develops small molecule pharmaceuticals to address unmet medical needs in cancer. We target novel cancer- driving pathways that can greatly synergize and enhance the therapeutic benefit of existing immunotherapies such as immune checkpoint inhibitors. Our molecules will cover a wide range of indications in cancer.
We have 4 different areas of drug discovery and development; 1) New generation of anti-cancer agents that can overcome resistance to existing targeted therapies 2) Small molecule agents that remove suppressive immune cells and increase effector immune cells in the tumor microenvironment 3) Hypoxia-targeting small molecule agents at tumor microenvironment 4) Anti-cancer Agents that simultaneously inhibit cancer cell proliferation and enhance immune cell activity against cancer cells